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ABSTRACT 
The ability to detect multiple disease-related targets from a single biological sample in a 
quick and reliable manner is of high importance in diagnosing and monitoring disease.  
The technique known as surface enhanced Raman scattering (SERS) has been developed 
for the simultaneous detection of multiple targets present in biological samples. 
Advances in the SERS method have allowed for the sensitive and specific detection of 
biologically relevant targets, such as DNA and proteins, which could be useful for the 
detection and control of disease.  This review focuses on the strengths of SERS for the 
detection of target molecules from complex mixtures and the clinical relevance of recent 
work combining SERS with multiplexed detection of biological targets. 
 
INTRODUCTION 
The sensitive and specific analysis of biomolecules from complex mixtures is essential 
in the field of clinical diagnostics.  The presence and progression of disease generally 
involves a multitude of different biomolecules; thus the detection of multiple events in 
tandem can reduce time and cost, as well as allowing significantly more information to 
be obtained from a small clinical sample. 
Raman scattering is an inelastic process involving the gain or loss of energy between an 
incident photon and the vibrational and rotational motions of a specific target 
molecule.1  The sharp, molecularly specific spectra that are obtained make it possible to 
specifically identify individual components from a mixture, therefore making it an ideal 
technique for the detection of multiple analytes.  Raman scattering is a relatively weak 
process with approximately only 1 in 106 photons being inelastically scattered.1  
However, it was discovered by Fleischmann et al.2 and developed by Jeanmaire and Van 
Duyne,3 that the Raman signal could be significantly enhanced by adsorbing the target 
molecule onto a roughened metal surface.4  This method, known as surface enhanced 
Raman scattering (SERS), produced enhancement factors of 104-108 in comparison to 
normal Raman scattering.5, 6  In order to achieve this enhancement, Au and Ag are the 
predominantly utilised metals as their surface plasmons lie in the visible region of the 
electromagnetic spectrum, which coincides with the laser excitation wavelengths 
commonly employed for Raman.  The metals are often used in the form of colloidal 
suspensions as these are relatively easily prepared and are compatible with solution-
based analysis.7  Furthermore, Au and Ag nanoparticles can quench fluorescence, which 
allows the use of fluorescent dyes as Raman labels.  The use of Raman labels is 
beneficial in obtaining further enhancement in the form of surface enhanced resonance 
Raman scattering (SERRS).  This occurs when the analyte contains a chromophore close 
in energy to the exciting radiation.  However, a dye label can also be used to achieve this 
enhancement if the chromophore is not present in the analyte itself.  This combination 
of resonance with surface enhancement has resulted in reported enhancements of up to 
1014 in comparison to normal Raman scattering.8 
Although the molecule of interest does not need to be directly adsorbed onto the 
metallic surface for SERS to be observed, the degree of enhancement is distance 
dependent.  This was demonstrated by Van Duyne et al. who found that when the 
distance between the target molecule and a silver substrate was greater than 2.8 nm, 
the SERS intensity decreased by a factor of ten.9  Therefore, it has been shown that to 
observe the most intense SERS signal, the target molecule must be within a few 
nanometers distance from the metal surface.  To enable target molecules to be within 
the required range, target molecules modified with thiol and amine groups have been 
used to enable the molecule of interest be adsorbed onto the metallic surface.10-13  
Furthermore, dyes have been specifically designed for use in SERS analysis with a 
chromophore, or reporter molecule, and a surface-seeking group to facilitate 
attachment to the enhancing metal surface.14-17  The suitability of these dyes in a 
multiplex detection system has also been demonstrated.16 
The use of SERS for the detection of biomolecules has been widely investigated and 
successfully applied for the direct detection of DNA,18, 19 proteins20 and cellular 
components,21 due to their unique Raman spectra.  Alternatively, as already mentioned, 
the target biomolecule can be labelled with a dye and detected, in this case the 
observation of the dye Raman spectra is indicative of the presence of the target DNA, 
proteins or of specific biological interactions.22-24  SERS is an ideal method of choice for 
clinical target detection, owing to its high levels of sensitivity and specificity due to the 
characteristic fingerprint spectra obtained.  SE(R)RS is a highly sensitive technique 
which has been shown to offer an improvement in detection limits of three orders of 
magnitude, in comparison to fluorescence, for the detection of dye-labelled DNA.25  
However, the main advantage SERS has compared to fluorescence spectroscopy is the 
ability to detect multiple components simultaneously within the same sample.  The 
peaks obtained in Raman spectra have narrow spectral widths, allowing for ease of 
spectral separation between components.  This is clearly advantageous over the broad 
fluorescence emission bands, which possess large spectral overlaps, making 
multiplexing more difficult and also providing limited structural information.  This is 
also the case for colorimetric detection where SERS offers greater sensitivity and an 
increased potential for multiplexed analysis.26  Culture-based methods are commonly 
employed in molecular diagnostics; however, these are time consuming and can be 
limited in sensitivity.27  Electrochemical sensing offers quick, simple and sensitive 
detection but has issues with interference, long-term stability and non-specific 
adsorption.28, 29  Microarray technology has also been widely investigated for diagnostic 
applications due to its high-throughput and multiplexing capabilities.30-32  Microarrays 
can be combined with each of the detection techniques mentioned, along with many 
others, to achieve the desired sensitivity along with the rapid detection of multiple 
biological targets.33-36  Compared to other methods available, advantages to using SERS 
include minimal sample preparation and the ability to detect target molecules in 
aqueous samples, as water exhibits very weak Raman scattering due to its small Raman 
cross-section.37, 38  This allows the analysis of biological samples in a multiplex format 
which is ideal for clinical applications.  Additionally, instrumental advances are allowing 
the development of handheld, portable instruments with comparatively low cost so that 
multiplexed ǯ
in a timely and accurate manner.39, 40  
The multiplexing capabilities of SERS have been demonstrated in the field of molecular 
diagnostics over the last decade.  A popular method of detection involves targeting 
specific DNA sequences that code for various diseases.  These methods are mainly based 
on the Watson and Crick base pairing where a probe sequence complementary to the 
target DNA sequence of interest is labelled with a fluorescent dye.41  There have been 
numerous clinical targets of interest detected, for example, different strains of the E. coli 
bacterium,42 three forms of the cystic fibrosis trans-membrane regulator (CFTCR) 
gene43 and three genes associated with methicillin-resistant S. Aureus (MRSA).44  
Nanoparticles have also been functionalised with DNA sequences to allow for target 
detection.  Graham and co-workers functionalised metallic nanoparticles with DNA and 
used the base pairing methodology to observe an increase in SERS signal due to 
controlled nanoparticle aggregation induced by DNA hybridisation.45  Following this, 
Vo-Dinh et alǤ  ǲ ǳǡ  consist of molecular beacons 
attached to the nanoparticle surface via a thiol group, for the multiplex detection of two 
breast cancer biomarkers.46 
SERS multiplexing has also made an impact on the detection of proteins where SERS 
analysis methods have been developed for the detection of specific antigens47 and 
protein interactions,48 to monitor specific biorecognition events49 and for the detection 
of cellular proteins.50  Successful SERS analysis of enzymes has also been applied, where 
the action of the enzyme results in the production of SERS-active dyes.51-54  This concept   ǢȾ-
galactosidase.55  
Multiplex SERS has also been extended to cellular detection.  Detection of proteins in 
vivo has been possible on a multiplex level using SERS for the detection of two cell ǡȾ2-adrenergic receptor and caveolin-356 and for the detection of two 
co-cultured cell lines using functionalised nanoparticles that targeted epidermal growth 
factor receptors (EGFR) and the HER2 biomarker expressed in breast cancer cells.57  
SERS has also been used to successfully detect multiple bacterial pathogens 
simultaneously.39, 58 Successful multiplex SERS analysis of tissue samples has also been 
achieved.  For example, SERS has been applied for the detection of prostate cancer 
biomarkers from prostate tissue samples.59, 60  
Therefore, SERS has been shown to be an ideal method of choice for multiplex detection 
and the technique meets the requirements for selective and sensitive detection in 
molecular diagnostics.  This review will focus on the various approaches, which have 
been developed for the use of SERS for the analysis of biomolecules, as well as the 
recent advancements of SERS in multiplex detection.  
 
DETECTION OF DNA BY SERS FOR CLINICAL APPLICATIONS 
The sensitive and specific detection of DNA sequences coding for particular diseases is 
extremely important when trying to understand disease progression and in developing 
novel detection methods.  Current methods of DNA detection, such as PCR and 
fluorescence, are limited in multiplexing capabilities and also pose issues such as 
contamination.  The molecule-specific Raman spectra with distinct narrow bands make 
the technique suitable for multiplexed analysis.  Furthermore, the high sensitivity of the 
technique means that strong Raman signals can be obtained from low sample 
concentrations, so that amplification is not always necessary, thus overcoming potential 
contaminations issues.  
 
Label-free DNA detection using SERS 
For successful SERS analysis, the analyte must be adsorbed onto or in close proximity to 
the enhancing metal surface.  Adsorption of DNA nucleotides directly onto a metal 
surface can allow the direct detection of a SERS signal from the constituent bases.18, 61-63 
Barhoumi and Halas investigated the SERS of thiolated single stranded and double 
stranded DNA oligomers bound to Au nanoshells.61  They found that thermal pre-
treatment of the DNA prior to adsorption onto the Au nanoshell changed the 
conformation of the DNA molecules, resulting in improved reproducibility of the SERS 
spectra.  They developed a spectral correlation function (SCF) to quantify differences in 
SERS spectra due to the chemical modification of adsorbed DNA and applied their 
method to monitor changes in the DNA spectrum resulting from conformational 
changes which occurs upon interaction with the chemotherapeutic agent cisplatin.  
They were able to observe greater spectral changes on interaction with cisplatin than 
with its analogue transplatin, which possesses a lower affinity for DNA, therefore it was 
postulated that the method could be used for studying the kinetics and interaction of 
DNA with various molecules.61  However, regardless of the DNA composition or base 
sequence, the spectra obtained from the DNA were similar and dominated by adenine 
due to its greater SERS cross section over the other bases.  In a further study, they used 
this concept to show that adenine can be used as a marker in a label-free SERS assay for 
the detection of DNA hybridisation.62  By substituting adenine with 2-aminopurine (2-
AP) in the probe sequence, the hybridisation characteristics of the probe were 
maintained while significant changes in the SERS spectra were observed.  This allowed 
the 2-aminopurine-substituted probe to be used for the detection of DNA hybridisation 
where hybridisation with the adenine-containing target sequence resulted in the 
presence of the adenine peak at 736 cm-1, which was not observed in the spectrum of 2-
aminopurine-substitued DNA or in the presence of the non-complementary control 
sequence.  The ratio of this adenine peak to the 2-AP peak at 807 cm-1 could be used to 
determine hybridisation efficiency, as the 2-AP peak was constant.  In both of these 
studies, the DNA sequences were thiolated to facilitate adsorption onto the metal 
surface; however, although label-free, this method of adsorption still requires 
modification of the DNA.61, 62 Additionally, non-specific adsorption of the DNA bases 
may occur which will result in different orientations on the metal surface compared to 
specifically oriented, covalently attached thiol modified DNA sequences.  Papadopoulou 
and Bell have shown that differences in orientation of thiolated DNA sequences on a 
metal surface can result in variations in the spectra obtained.64  They also investigated 
the variation in SERS spectra of the DNA base adenine, deoxyadenosine and 
deoxyadenosine- ?ǯ-ȋ ?ǯ-dAMP) with changes in experimental conditions 
such as pH.65-67  Recent work from this group has shown that SERS detection of 
unlabelled single and double stranded DNA is possible without the need for labelling, 
thiolation or use of linkers.19, 68 By allowing spontaneous adsorption of the DNA onto Au 
and Ag nanoparticles via the nucleotide side chains, spectra were recorded with high 
signal to noise and excellent reproducibility. Changes in Raman bands were observed 
corresponding to each of the bases, which could be attributed to the difference in 
scattering cross sections between the different bases.  This method has been applied to 
the detection of single base mismatches, in this case spectra were collected for different 
DNA sequences before being digitally subtracted to give a difference spectrum with 
positive and negative features corresponding to the changes in base sequence.19  An 
extension of this work enabled the detection of both single and double stranded DNA at 
10-9 M, as well as the separation of five DNA sequences corresponding to five different 
strains of E. coli bacteria without any need for multivariate analysis.68  Figure 1 shows 
the spectra obtained for the five different E. coli DNA sequences as well as the number 
of each of the four bases present in each strand.  It can be observed that visible 
differences are present in the spectra, relating to the different compositions of the DNA 
sequences.  For example, the adenosine ring breathing mode at 737 cm-1 and the large 
adenosine band at 1329 cm-1 are more intense in the spectrum of strains 4 and 5 where 
there are more adenosine nucleotides present.  This shows that the simple method can 
be applied for the detection of biologically relevant samples without any need for 
modification or labelling.  They also observed small changes in spectra when the order 
of the bases was changed, indicating that this method could also potentially be used to 
obtain information on the order of bases in the DNA sequence. 
 
 
Figure 1. SERS spectra of five single stranded DNA sequences corresponding to five different strains of E. coli, recorded 
on hydroxylamine hydrochloride reduced silver nanoparticles at 10-6 M DNA.  The number of each of the four nucleotide 
bases are indicated for each sequence.68  Reprinted by permission of John Wiley and Sons. Copyright © 2012 WILEY-VCH 
Verlag GmbH & Co. KGaA, Weinheim. 
 
Guerrini et al. have recently applied the use of spermine-stabilised silver nanoparticles 
for the direct analysis of DNA duplexes.69  The positively charged silver nanoparticles, 
originally prepared by van Lierop et al.,70 were able to undergo controlled aggregation, 
which provided the hotspots required for SERS but without over aggregation of the 
sample.  This means that no aggregating agent is required as the DNA itself induces the 
aggregation into small clusters via electrostatic interactions.  As well as simplifying the 
analysis, this increases stability which permits analysis over a greater period of time.  
Using these nanoparticles, significant information could be obtained without a need for 
labelling or DNA amplification.  Furthermore, single base mismatches and base 
methylations could be detected from DNA duplexes for the first time using SERS.  The 
sensitive assay was highly reproducible between batches, providing a useful and 
efficient method of analysis.69 
 
SERS detection of dye-labelled DNA 
Although label-free detection has its advantages, it is limited in its capabilities for 
diagnostic applications as it is very challenging to accurately determine the specific 
order of the bases in the DNA sequence from the SERS spectrum.  The use of dye-
labelled DNA allows the monitoring of signal variations arising from the presence or 
absence of target sequences related to disease.  In these applications the target DNA will 
not be labelled, therefore a sequence complementary to the target is generally utilised 
and labelled so that when hybridisation to the target sequence occurs, a change in the 
signal arising from the dye label can be observed, allowing detection of a specific target 
sequence.  Hybridisation events give the required selectivity as these are based on 
Watson and Crick base pairing,71, 72 while the narrow bands present in the SE(R)RS 
spectra of dyes introduce the potential for multiplexed analysis.  Various approaches for 
the SERS detection of dye-labelled DNA sequences have been investigated, with 
sensitivity approaching the level of single molecule detection.14, 24, 41, 73-77  Many of these 
assays use spermine hydrochloride to facilitate the adsorption of the DNA to the metal 
surface for successful SERS analysis.  The spermine forms electrostatic layers, allowing 
the negative DNA to adsorb onto the negatively charged nanoparticle surface.  
Furthermore, this induces aggregation forming the hotspots required to obtain intense 
SERS signals.73  
When dye labels are used, careful consideration of the properties of the dye must be 
made in order to achieve optimal SERS signals and the largest possible discrimination 
between target and controls.  It is important to consider how the dye may interact with 
other assay components as this could affect overall performance.  In a recent study, 
Gracie et al. compared two bases, spermine and triethylamine (TEA), and optimised the 
experimental conditions for FAM- and TAMRA-labelled DNA.78  They found that dye-
spermine and dye-DNA interactions cause changes in the observed fluorescence 
intensity, which is also dependant on experimental conditions such as the pH and 
concentration.  It was also observed that these fluctuations in intensity are dependent 
on the particular dye label used and therefore careful consideration must be made when 
considering the experimental design for SERS-based DNA detection using dye-labelled 
DNA.  This is of particular importance for multiplex assays where multiple dyes are 
used, since changes in signal could be mistaken for varying amounts of target. 
When DNA is double stranded and therefore in its coiled conformation, the negative 
charge of the backbone results in repulsion from the negatively charged nanoparticle 
surface.  In contrast, single stranded DNA is uncoiled with the bases exposed, which 
have an affinity towards the negative metal surface.68  Therefore, adsorption of single 
stranded DNA to a colloidal metal surface is more efficient than that of double stranded 
DNA, which is clearly a significant advantage when using SERS for the detection of DNA.  
This concept has therefore been extensively studied and exploited in DNA detection 
assays.44, 79, 80  Following on from a study by MacAskill et al.,44 Harper and co-workers 
studied the varying affinity of dye-labelled DNA to the surface of silver nanoparticles 
and the effect these differences have on the overall SERS response.81  A difference in the 
intensity between dye-labelled single stranded and double stranded DNA was observed, 
with the single stranded DNA giving the largest response.  It was also found that no 
SERS signal was obtained for the dye alone under the conditions used, indicating that 
without the DNA   ǯ       , thus 
proving that the DNA rather than the dye drives the adsorption.  Importantly, it was 
shown that by optimising experimental conditions such as pH, volume of colloid and salt 
concentration of buffers, the largest possible discrimination between single and double 
stranded DNA could be achieved so that the system can be successfully applied to assays 
that use the difference in SERS response of single and double stranded DNA for the 
detection of target DNA.  Therefore when designing an assay it is ideal that single 
stranded DNA is detected rather than double stranded DNA, however, commonly the 
case is the opposite where the DNA becomes double stranded upon hybridisation with 
the target DNA sequence.  This would result in a negative assay where the SERS signal is ǲ  ǳ   ǲ  ǳǤ44  Although a change in signal is still observed, 
negative assays are unfavourable as it can be difficult to distinguish between a 
reduction in signal due to the presence of target or because of other reasons such as 
poor assay performance.  Furthermore, it can be very challenging to multiplex using this 
assay type.  In order to overcome the disadvantages of negative assays, van Lierop et al. 
developed a SERS primer assay.79  In this work, the target sequence was the femA gene 
of Staphylococcus epidermidis, which can be used for bacterial identification of 
Staphylococcus epidermidis and Staphylococcus aureus.  The SERS primer contains a dye-
labelled region that was rendered single stranded when DNA hybridisation occurs with 
a specific target sequence.  When these SERS primers are closed, they are 
predominantly double stranded DNA and therefore do not adsorb strongly onto the 
nanoparticle surface (Figure 2). However, when target is present, it will hybridise to the 
SERS primer, which then opens the partly self-complementary region of the primer, that 
contains a single stranded region with a dye label attached, allowing for adsorption onto 
the nanoparticle surface resulting in an increased SERS response.  This separation-free, 
positive assay was successfully applied for the detection of femA bacterial DNA, as well 
as PCR product from the amplification of 1 ng genomic DNA from Staphylococcus 
epidermidis, showing the applicability of the SERS method for the detection of 
biologically relevant samples. 
 
 Figure 2. When no target is present (A), the SERS probe is closed and the DNA is double stranded and therefore unable 
to adsorb onto the nanoparticle surface.  When complementary target is present (B) this displaces the partly self-
complementary region of the primer, destabilised by mismatches, leaving the dye-labelled single stranded DNA able to 
adsorb onto the nanoparticle surface to give an increased SERS response.79 Reprinted with permission from D. van 
Lierop, K. Faulds and D. Graham, Anal. Chem., 2011, 83, 5817-5821. Copyright © 2011 American Chemical Society. 
 
The optimisation of the SERS primers and demonstration of their capabilities in 
different assay types was further investigated to determine how the SERS primers 
performed in model assay systems.82  The synthetic model systems were used to 
optimise parameters such as the specific design of the primers, type of nanoparticles 
and the nanoparticle and analyte concentration.  The results of these experiments led to 
the development of a new assay which involved the SERS primers being incorporated          ?ǯ- ?ǯ   Taq DNA 
polymerase.82 
Harper et al. developed a new detection assay based upon the commonly used TaqMan 
assay, where SERS detection was used to improve sensitivity over the commonly 
employed fluorescence detection.83  TaqMan assays involve enzymatic probe cleavage 
where the TaqMan probe contains both a fluorophore and a quencher, connected by a 
DNA sequence, allowing quenching of the fluorescence due to the close proximity of the 
fluorophore and the quencher.84, 85  The TaqMan probe hybridises to the target 
sequence at a site adjacent to the primer binding site and, during PCR, the Thermus 
aquaticus (Taq) polymerase enzyme will both amplify the target DNA and, in the 
process, digest the TaqMan probe.  Upon digestion, the distance between the 
fluorophore and the quencher will be increased resulting in increased fluorescence 
signal, which is proportional to the amplification of the target sequence.  The TaqSERS 
assay developed in this work required the design of a DNA probe containing a SERS-
active dye compatible with the enhancing metal surface.  The optimum probe design  ?ǯ  ? ?
sequence, which was a sequence within the MRSA bactǤ    ?ǯ 
consisted of a HEG-spacer, to terminate enzyme progression, followed by 10 adenine ǡǡ ?ǯǤ ? ?
a tail and facilitates adsorption of the DNA onto the colloidal surface since dye-labelled 
DNA gives a stronger SERS response than dye alone, this results in an increase in SERS 
signal.83, 86  Following amplification of the template and digestion of the probe to 
separate the biotin and the TAMRA dye, any undigested probe was removed from the 
mixture using streptavidin-coated magnetic beads so that SERS signal was only 
obtained from the TAMRA from the digested probe (Figure 3).  As well as the target 
sequence coding for the methilin resistant mecA gene from MRSA, the authors analysed 
a nonsense sequence, which did not contain a region complementary to the mecA probe 
region so that no hybridisation or digestion should occur.  They found that, in 
comparison to the nonsense sequence, a much more intense SERS signal from the 
TAMRA dye was observed in the presence of the target sequence, proving that the assay 
was sensitive and specific to the target.  The sensitivity of the assay was also studied 
and a comparison was carried out between SERS detection and fluorescence detection, 
which is normally the method of choice for this assay type.  It was shown that this new 
TaqSERS assay could achieve detection limits an order of magnitude lower than when 
using the more conventional fluorescence detection method.  In addition, the novel 
assay with SERS detection overcomes issues such as high background signal and broad 
overlapping peaks, which limit the use of the assays for simultaneous detection of 
multiple DNA sequences by fluorescence. 
 
 Figure 3. TaqSERS assay; (i) hybridisation of TaqSERS probe, a, target sequence, b, and primers, c, (ii) Taq polymerase 
enzyme simultaneously elongates primers and digests probe, (iii) streptavidin-coated magnetic beads are introduced to 
remove any undigested biotinylated probe and free biotin, (iv) magnet removes beads from system leaving TAMRA 
ǮǮǯǯǡȋȌ-reduced silver nanoparticles with spermine hydrochloride 
(0.1 mol dm-3) were added. Within 5 min the SERS spectrum was recorded using 514.5 nm laser excitation.83 Reproduced 
from Ref. 71 with permission from The Royal Society of Chemistry.  
 
In an alternative approach, Dougan et al. developed an exo-SERS signal amplification 
assay using the enzyme lambda exonuclease, where the aim was to amplify the signal 
rather than the amount of target present, for the detection of chlamydia trachomatis.86          ?ǯ    ǡ
with a 15 base detection region which was complementary to a region of the target 
sequence.  This was followed by a HEG spacer to stop the enzyme activity then 10  ?ǯȋȌǤ-
specific adsorption and digestion and allow separation of unhybridised probe, a split 
probe system was designed where the reporter and biotinylated capture probes 
hybridise to the same target sequence in a sandwich format (Figure 4).  The target, 
reporter and capture probes were hybridised before being captured on streptavidin-
coated magnetic beads.  After thorough wash steps to remove excess probe, lambda-
exonuclease was added and DNA digestion was allowed to occur.  Supernatant was 
separated from magnetic beads and added to citrate-reduced silver nanoparticles 
followed by addition of spermine hydrochloride and SERS analysis using 532 nm laser 
excitation wavelength.  TAMRA signal was observed in the presence of target but not 
when any components were missing from the assay.  To determine if the assay was 
quantitative, the concentration of target was varied with all other components 
remaining constant.  A linear concentration versus intensity curve was obtained, which 
was impressive considering the number of events taking place (hybridisation, washing 
and enzyme activity) and proves that the assay was working effectively.  When the 
assay was applied to chlamydia trachomatis PCR product, a clear distinction was 
observed between target and nonsense DNA sequence and a detection limit was 
obtained which was comparable to molecular beacon assays. 
 
 
Figure 4. Schematic representation of the exo-SERS assay.  Hybridisation between the unlabelled target, a, the capture 
probe, b, and the reporter probe, c. (ii) the duplex is captured on streptavidin-coated magnetic beads, d, before washing 
to remove excess probe (iii). (iv) lambda-exonuclease, e, is incubated with the beads and the supernatant is removed and 
added to diluted citrate-reduced silver nanoparticles with the addition of spermine hydrochloride (v) before SERS 
spectra were recorded at 532 nm laser excitation wavelength.86  Reproduced from Ref. 74 with permission from The 
Royal Society of Chemistry. 
 
Although these assays have been applied for the detection of clinically relevant targets 
and have shown potential for multiplexed analysis, the detection of multiple targets was 
not demonstrated in the work discussed.  Since the focus of this review is multiplex 
detection, the following section will discuss how these different assay formats have 
been applied for the detection of multiple DNA sequences using SERS. 
 
Multiplex detection of disease-related DNA targets 
The simultaneous detection of multiple disease-related DNA sequences from one 
sample could result in simplified, efficient and cost-effective detection and diagnosis of 
diseases.  Due to the compatibility of SERS for the analysis of biological samples, as well 
as the advantages of SERS for multiplexed analysis, the technique is a suitable candidate 
for the detection of multiple clinical targets.  Consequently, SERS has been extensively 
investigated for the multiplexed detection of DNA sequences and has been successfully 
applied for the analysis of biologically relevant targets.43, 44, 76, 77, 87-90  For example, the 
multiplexed detection of DNA sequences has been carried out to identify 5 different 
labelled DNA sequences using two excitation wavelengths without the need for any data 
analysis.76  The detection of 6 labelled DNA sequences was also carried out using one 
excitation wavelength with the aid of chemometrics for deconvolution of the data77 and 
also using Bayesian statistics methods.91  
Recently, Gracie et al. further developed the exo-SERS split probe assay discussed 
previously (Figure 4) for the detection of multiple gene sequences.92  They applied the 
assay, based on the activity of lambda-exonuclease, for the detection of three bacterial 
meningitis pathogens: Neisseria meningitidis, Streptococcus pneumonia and Haemophilus 
influenzae.  By using chemometrics, each of the three pathogens in the multiplex were 
quantified.  The detection of each pathogen was carried out individually to determine 
the sensitivity of the assay, followed by the design of a triplex to detect the three DNA 
sequences simultaneously, with chemometric analysis for the quantification of each.  A 
synthetic target pathogen sequence was hybridised to two DNA sequences, one             ?ǯ-phosphate.  
Streptavidin-coated beads were added to attach to the fully formed duplex DNA before 
wash steps were carried out to remove any excess/unhybridised DNA from the mixture.  
Lambda-   ?ǯȋ
the fluorescent dye attached) resulting in release of the dye from the DNA duplex, 
attached to the streptavidin-coated beads.  The digestion products were then added to 
citrate-reduced silver nanoparticles with addition of spermine prior to analysis by SERS.  
For each of the three pathogens, picomolar detection limits were obtained using FAM, 
TAMRA and Cy3 as labels and 532 nm laser excitation wavelength.  The lower detection 
limit was comparable to the previous use of the assay for the detection of chlamydia 
trachomatis.86   PCR was then carried out on plasmid DNA from each pathogen and the 
assay was applied for the detection and quantification of the target sequences from PCR 
product.  Even though the spectra are similar, peak differences could be observed 
between each of the dyes and so multiplexing was possible. Figure 5 shows the 
spectrum obtained for each individual dye, corresponding to each of the three bacterial 
meningitis pathogen DNA sequences, as well as the spectrum for the multiplex sample.  
Here it can be clearly observed that there is at least one peak exclusively present in each 
dye spectrum and the individual peaks for each dye can also be observed in the 
multiplex spectrum, indicating that each of the three pathogens can be identified from 
the mixed sample.  Further to the detection of each individual pathogen, a chemometrics 
model was built which was able to quantify each of the pathogens in the sample.  This 
was the first time SERS was used for the detection and quantification of each 
component in the multiplex, with consistent results obtained much quicker than with 
the conventional culture-based method.  This assay is potentially applicable to a wide 
variety of diseases and thus shows promise in clinical applications.  This has recently 
been demonstrated when the assay was applied to the simultaneous detection of two 
bacterial pathogens in clinical samples obtained from meningitis patients.93 
 
 Figure 5. SERS spectra obtained from the simultaneous detection of all three bacterial meningitis pathogens using the 
Exo-SERS assay (a) and the SERS spectra obtained from the PCR product of each pathogen separately; N. meningitidis 
(b), H. influenzae using (c) and S. pneumonia (d). Red dotted lines show peaks that are unique to each SERS spectrum 
and hence each pathogen.92  Reproduced from Ref. 80 with permission from The Royal Society of Chemistry. 
 
Another approach in SERS-based detection of DNA is using nanoparticles functionalised 
with two non-complementary DNA sequences, which are both complementary to the 
target sequence.  Therefore, when the target is introduced, hybridisation occurs 
resulting in the aggregation of the sample.  This nanoparticle assembly has been 
exploited for the detection of DNA sequences for several years, the first reported by 
Graham et al. in 2008 where three different DNA sequences were detected using DNA-
functionalised silver nanoparticles combined with SERS-active reporter molecules.45, 94-
97 This method has recently been combined with the use of magnetic manipulation for 
the sensitive detection of two DNA sequences, both individually and in a duplex.98  In 
this work, Donnelly et al. used DNA-functionalised silver nanoparticles and DNA-
functionalised magnetic nanoparticles, where the nanoparticles were each 
functionalised with a different 12-base DNA sequence that were both complementary to 
a section of the 24-base target DNA sequence.  The silver nanoparticles were also 
functionalised with a SERS reporter molecule so that when the target was introduced, 
hybridisation occurred between the two probes resulting in aggregation of the 
nanoparticles due to the reporter molecules location in hotspots between the particles.  
Therefore, in the presence of the target DNA, a strong SERS signal could be obtained 
from the Raman reporter.  An external magnet was used in order to concentrate the 
sample and excess material was removed by washing prior to direct SERS analysis of 
the magnetic plug.  This assay was used for the detection of specific Candida fungal 
species important in the detection of fungal infections: C. krusei was detected by 
monitoring the Raman spectrum of 4-mercaptopyridine (MP) and C. albicans using 
malachite green isothiocyanate (MG) as the reporter on the silver nanoparticle 
conjugates.  A detection limit of 20 fmol was obtained for each of the two target 
sequences, giving a ten-fold improvement over using suspension-based systems.  The 
assay was then applied for the detection of both sequences using a mixture of the two 
probes and a strong MP signal was obtained in the presence of the C. krusei target 
sequence and the MG signal was strongest when the C. albicans was present.  Although 
small background signals were observed, the presence of each target gave clearly 
distinguishable results.   ǲ ǳ ȋȌ     -ǯ   
sensitive and specific detection of multiple DNA sequences.46  In this approach, two MS 
nanoprobes were designed for the detection of separate DNA sequences.  The probes 
consist of a DNA hairpin with a Raman probe at one end and a thiol group at the other to 
attach to the metal surface.  Without the target DNA, the MS probe is in a hairpin loop so 
that the Raman reporter is close to the metal surface resulting in a high SERS signal.  
Hybridisation of a complementary sequence separates the probe from the metal surface 
thus decreasing signal.  Since SERS decreases when the target hybridises to the probe,     ǲ  ǳ       Ǥ
However, the assay has been successfully applied for the detection of multiple DNA 
sequences without a need for target labelling or wash steps.  This work has recently 
been further developed into a SERS-based molecular sentinel-on-chip (MSC) assay 
(Figure 6).99  This MSC assay involved the functionalisation of a nanowave chip with MS 
probes to detect DNA sequences for the diagnosis of viral infections.  The nanowave 
chip used in this work was a plasmonic substrate developed by Vo-Dinh in 1984.100  
This metal film over nanosphere (MFON) is a close-packed nanosphere substrate with a 
thin gold film that provides a high enhancement factor with low production costs and 
high reproducibility.  In the current work, a bimetallic film (Ag and Au) was used, as 
opposed to the Au film used previously, to provide further SERS enhancement.  To 
investigate this enhancement, the authors fabricated Au film over nanosphere (AuFON) 
and bimetallic film over nanosphere (BMFON) substrates and found that BMFON 
exhibits a 3.6 times greater SERS signal than the AuFON.  This can be explained by the 
fact that the BMFON has greater surface roughness than the AuFON and its LSPR is red-
shifted due to the greater nanoprotrusions. 
 
 
Figure 6. Schematic representation of the MSC approach for the multiplex detection of two target DNA sequences.  
BMFON substrates are functionalised with MS probes.  When no target is present, the hairpin loop is closed and SERS 
signal is observed.  On hybridisation with the target DNA sequence, the probe is opened resulting in a decreased SERS 
signal due to separation of the reporter molecule with the metal surface.99  Reprinted from Springer, Analytical and 
Bioanalytical Chemistry, volume 406, 2014, page 3338, H. T. Ngo, H. N. Wang, T. Burke, G. S. Ginsburg and T. Vo-Dinh, 
Figure 1, © Springer-Verlag Berlin Heidelberg 2014. With kind permission from Springer Science and Business Media. 
      ?ǯ   ȋ ?Ȍ        ?ǯ         
substrate.  Each hairpin was at least 35 bases (~10 nm) in length to allow for effective 
separation of the probe from the metal surface upon hybridisation.  The BMFON 
substrates were functionalised with the MS probes, interferon alpha-inducible protein 
27 (IFI27) and interferon-induced protein 44-like (IFI44L), both individually and as a 
mixture in order to demonstrate the separate detection of the targets, as well as 
multiplex detection.  For individual detection, a decrease in the SERS signal for the dye 
label (Cy5 or ROX) was observed when single stranded complementary DNA was 
present, compared to when no ssDNA was present or when non-complementary DNA 
was present.  This proves that the Raman labels were separated from the nanowave 
surface when hybridisation occurred between the probe and single stranded 
complementary target DNA.  When a mixture of the two nanoprobes were analysed, a 
reduction in signal for each dye was observed when the complementary DNA was 
present and for the individual probes when only complementary target was introduced.  ǲǳ
the system can be used for multiplex detection; however, the authors used a parameter 
they developed previously101 called relative diagnostic index (RDI), to convert the ǲǳǡerred.  This assay 
was the first use of the MSC approach for the label-free multiplex detection of genetic 
disease biomarkers.  The fact that the assay requires only a single hybridisation step 
and has no need for washing is advantageous, as is the lack of requirement for labelling Ǥǲǳ
nanobiosensor for the detection of DNA.102  This was a proof of concept for the novel ǲǳ for multiplexed detection, however, a 
limit of detection of approximately 0.1 nM for target DNA was obtained.  Since the 
authors used significantly small amounts of sample (2 ɊȌǡy estimated the absolute 
limit of detection to be 200 amol.  
Kang et al. have developed a Au particle-on-wire system which involves the self-
assembly of Au nanoparticles onto Au nanowires in the presence of target DNA, 
resulting in a SERS signal which is proportional to the amount of target present in the 
sample.103  Au nanowires were functionalised with thiolated DNA probes and Au 
nanoparticles were functionalised with reporter DNA molecules containing a Cy5 label.  
After blocking remaining sites on the Au nanowire surface, incubation with target DNA, 
which contains sequences complementary to the immobilised DNA probes and the 
reporter DNA, results in the capture of the target DNA in a sandwich format while 
creating SERS hotspots between the nanowire and nanoparticle gap (Figure 7(a)).  This 
results in a high SERS signal being obtained characteristic of the Cy5 Raman reporter 
(Figure 7(b)), which increased with increasing concentration of target DNA resulting in 
a lower detection limit of 10 pM.   
 Figure 7. (a) Schematic representation for the detection of target DNAs by Au particle-on-wire system. (b) SERS spectra 
collected using 633 nm laser excitation in the presence of complementary target-reporter DNA sequences (blue 
spectrum) and that of a single Au NW prepared by non-complementary target DNA sequences (magenta spectrum). The 
inset is UV-vis absorption spectra of Au NPs (green spectrum), Au NWs (magenta spectrum), and Au particle-on-wire 
systems (blue spectrum) illustrating why the 633 nm laser excitation was selected. (c) SEM image of a typical Au 
particle-on-wire structure constructed by adding complementary target DNA sequences (top) and a clean NW in the 
presence of non-complementary target DNA (bottom).103 Reprinted with permission from T. Kang, S. M. Yoo, I. Yoon, S. Y. 
Lee and B. Kim, Nano Lett., 2010, 10, 1189-1193.  Copyright © 2010 American Chemical Society. 
 
To test the system in a multiplex format, the Au nanowires were functionalised with two 
different probe sequences and incubated with a mixed solution of two target DNA 
sequences.  Distinguishable SERS spectra were obtained for each of the two Raman 
reporters, Cy5 and TAMRA, with no cross-hybridisation occurring.  The Au 
nanoparticle-on-wire system was then applied for the simultaneous detection of PCR 
product of four pathogenic DNA sequences: Enterococcus faecium, Staphylococcus 
aureus, Stenotrophomonas maltophilia and Vibrio vulnifus, to demonstrate its 
applicability as a diagnostic assay.  Although a decrease in SERS signal was observed 
when all four targets were present, each pathogen could be correctly identified from the 
mixture.  Furthermore, the assay was applied for the detection of the four bacterial 
pathogens from real clinical samples, where target pathogenic DNA was extracted from 
cerebrospinal fluid, stool, pus and sputum, with results comparing well to those 
obtained from the conventional culture-based method.  This system has therefore 
shown significant promise for application in clinical diagnostics and demonstrates the 
potential of SERS as a detection technique for bioanalysis of clinical samples. 
Au nanoparticle-decorated silicon nanowire arrays (AuNPs@SiNWAr) have been 
reported to give an excellent enhancement factor when used as a SERS substrate.104-106  
Wei et al. have recently utilised these substrates for the multiplexed detection of DNA 
using a molecular beacon-based system.107  Dye-labelled stem loop DNA sequences 
were immobilised onto the AuNPs@SiNWAr and in the absence of target DNA, a SERS 
signal is obtained from the dye label.  When target DNA is present, the stem loop opens, 
separating the dye molecules from the Au nanoparticle surface and resulting in a 
decrease in signal.  This was applied for the detection of synthetic DNA sequences with a 
10 fM detection limit which is comparable to positive assays, although this approach 
still has the disadvantages of being a negative assay.  Nonetheless, the assay was applied 
for the detection of three DNA strands, labelled with three different dyes, and 
distinguishable signals were obtained.  Since the fabrication of these substrates is low 
cost and accessible, the authors envisage potential for this technique in SERSȂbased 
sensing applications.  
The use of SERS for the detection of disease-related target DNA sequences and the 
advancements in methods for application in multiplexed analysis have been discussed 
herein.  Parallel to the success in DNA analysis, SERS has also been applied for the 
detection of multiple proteins relating to disease.  The following section focusses on the 
development of SERS-based methods for the detection of proteins for diagnostic 
applications.  
 
SERS-BASED PROTEIN DETECTION FOR CLINICAL APPLICATIONS 
The understanding of specific protein interactions can provide abundant information on 
particular biological pathways, especially in disease progression.  Furthermore, 
detection of specific disease-related protein biomarkers can be invaluable for the 
detection and diagnosis of disease.  Compared to amplification methods used for DNA, 
such as the polymerase chain reaction (PCR), there are no such available methods for 
protein amplification.  Therefore, it is crucial that highly sensitive detection methods 
are developed for the detection of the low concentrations of proteins present in 
biological samples.  Highly sensitive methods involving electrochemistry108-110 and 
fluorescence spectroscopy111, 112 have been developed for the specific detection of 
protein-protein interactions.  However, as discussed previously, SERS has some 
advantages over these methods and the technique has therefore been extensively 
applied for the analysis of proteins, with detection at the single molecule level being 
achieved.113-115 Although there are potential limitations to a direct SERS approach, 
mainly the permanent damage to the native protein structure, these issues can be 
overcome with careful consideration of the experimental conditions and the SERS 
substrate used for analysis.116-120  
 
Label-free protein detection by SERS 
Proteins can be referred to as simple, where they consist of only amino acids, or they 
can be conjugated, where the protein is covalently attached to a prosthetic group.  SERS 
studies of simple proteins was performed many years ago,121, 122 where the focus was on 
the method of attachment of the proteins to the metallic surface, for example, through a 
carboxyl group or an amine group.  Haemoproteins are the most commonly known 
conjugated proteins characterized by SERS.  The SERS spectra of haemoproteins are 
easier to interpret compared to the spectra of simple proteins, as almost all of the SERS 
bands arise from the haem group.  An example of this is the extensive SERS analysis of 
cytochrome c, where information on the molecular orientation,117, 123 electron transfer 
mechanism124, 125 and the ability to detect single molecules was achieved.126, 127  SERS of 
haemoglobin has also been reported,113 and further to this, the oxygen released from 
haemoglobin monitored by SERS.128  Moreover, Feng et al. have also successfully 
characterised the native structure of myoglobin using SERS.116    
More recently, novel methods have been developed based on a label-free detection 
approach.  Wang et al. successfully monitored the progression of colorectal
the SERS spectra obtained from serum proteins and compared the spectral differences 
between serum proteins from cancer patients and those from healthy volunteers.129  
Principle component analysis (PCA) and partial least square regression (PLS) 
demonstrated the high level of accuracy of the proposed SERS method with 99.5% and 
93.5% levels of accuracy obtained, respectively.  Another novel SERS method for the 
detection of adenoviral conjunctivitis was proposed by Choi et al. in 2014.130  The 
method, which involved drop-coated deposition surface enhanced Raman scattering 
(DCD-SERS), required very low sample volumes (2 ɊȌ     give highly 
reproducible SERS spectra.  Erythropoietin was also detected using SERS without the 
need for Raman labels with high levels of sensitivity (LOD 3.5x10-13 M).131  The 
substrate used here was composed of gold nanoparticles with an ultrathin silica shell 
and an erythropoietin-specific antibody attached to the surface.  The detection was 
based on the conformational changes that the antibody undergoes in the presence of 
erythropoietin by comparing the SERS spectra of unreacted substrate to that in the 
presence of the specific target protein.  This method was also extended to the successful 
detection of caffeine.131 
C-reactive protein (CRP) is a biological marker of infection and inflammation.  Sensitive 
detection of the protein is therefore important for diagnostic applications.132, 133  Kim et 
al. have recently developed a label-free SERS method for monitoring CRP-ligand specific 
interactions.134  They used a substrate comprised of concentration-induced silver 
nanoparticle aggregates that possessed a phosphocholine-terminated self-assembled 
monolayer, with a high affinity for CRP.  Due to the short distance between the CRP and 
the metallic surface (<0.4 nm), a high level of sensitivity was obtained with a reported 
limit of detection of approximately 100 fM.  Most recently, Kahraman et al. designed a 
metallic 3D structure to detect six different proteins (bovine serum albumin (BSA), 
haemoglobin, thrombin, avidin, cytochrome c and lysozyme) using SERS without the 
need for Raman labels.135  The metallic structures were produced via nanopatterning 
with latex nano/microparticles combined with Cr and Ag sputtering.  This method 
generated nanovoids within the 3D structure that allowed for the generation of protein 
specific SERS spectra that were background free with reported protein concentrations 
of 0.05 ɊȀǤ  PCA analysis was used, which demonstrated the significant differences 
present in the SERS spectra between the six proteins, allowing for successful label-free 
SERS detection (Figure 8).   
  
Figure 8. SERS spectra of hemoglobin, cytochrome c, lysozyme, BSA, avidin, and thrombin dropped on the nanovoid 
Ǥ ? ?Ǥ ?Ɋ ?1.135 Reprinted from Analytica Chimica Acta, Vol 856, M. 
Kahraman and S. Wachsmann-Hogiu, Label-free and direct protein detection on 3D plasmonic nanovoid structures using 
surface-enhanced Raman scattering, pages 74-81, Copyright © 2015, with permission from Elsevier. 
 
Indirect detection of proteins using SERS 
As mentioned above, SERS is an ideal method of choice for the analysis of specific 
protein interactions and with the addition of Raman reporters the levels of sensitivity 
can be improved.  Similarly to the detection of DNA, labelled proteins can be adsorbed 
onto the enhancing metal surface with the use of an aggregating agent to create the 
desired hotspots between the metal particles.136  Alternatively, aggregation can be 
induced using a specific nanoparticle assembly approach.  In 2012, Robson et al. 
developed a SERS-based assay for the detection of the mouse double minute (MDM2) 
protein, which plays a critical role in the progression of many cancers.137  The method 
involved using a peptide mimic of the tumour suppression protein, p53, which is 
negatively regulated by MDM2, chemically attached onto the surface of silver 
nanoparticles.  In the presence of MDM2, the p53-functionalised nanoparticles 
underwent assembly, resulting in a significant increase in the SERS intensity of the 
reporter (benzotriazole dye) also present on the silver nanoparticle surface.  Based on a 
similar methodology of nanoparticle assembly, Craig et al. designed a SERS detection 
method for specific carbohydrate-protein interactions, in particular, the interaction 
between the lectin protein ConA and lactose-functionalised nanoparticles (Figure 9).138  
The specific sugar used to functionalise the nanoparticles has four potential binding 
sites, meaning that multiple carbohydrate-lectin interactions can occur simultaneously, 
allowing for nanoparticle aggregation to occur and therefore increasing the overall 
SERS intensity of the benzotriazole dye present.  Due to the high sensitivity of the SERS 
method, limits of detection as low as 40 pM were achieved which was a significant 
improvement over alternative detection methods.  This study was a proof of concept 
that this method could be used for the highly sensitive monitoring of interactions 
between carbohydrates and ligands; however, the next step was to use this method to 
monitor these interactions in a cellular environment.   
 
 
Figure 9. (top) Aggregation resulting from the interaction between ConA and the glyconanoparticles. (bottom) SERS 
spectra with and without the addition of ConA.138  Adapted from Ref. 125 with permission from The Royal Society of 
Chemistry. 
 
In 2014, Craig et al. used lectin-functionalised nanoparticles to monitor the expression 
of specific carbohydrate species at the cellular interface.  By exploiting the difference in 
expression of glycans in cancerous and noncancerous cells, this method proved to be 
successful in the discrimination between healthy and cancerous prostate cells.139  
Simpson et al. have recently applied the use of glyconanoparticles for the sensitive and 
specific detection of cholera toxin B-subunit (CTB) from synthetic freshwater, to levels 
as low as 56 ng/mL.140  Particles were functionalised with a mixture of carbohydrates, 
sialic acid and galactose, to mimic the binding of CTB with the GM1 ligand on the surface 
of intestinal cells.  The mixed carbohydrate coating was required as this increased the 
response significantly in comparison to functionalising with sialic acid or galactose 
alone.  The selectivity of the method was shown as no aggregation, and thus a reduced 
SERS response, was obtained when ConA was present in place of CTB.  The observed 
detection limit was 50 times better than that achieved using UV-Visible extinction 
spectroscopy and within the recommended detection range for cholera toxin.  This 
sensitivity also matches the limits of current WHO approved tests. 
 
Protein Detection using SERS-based Immunoassays 
The ability to detect and quantify specific protein biomarkers provides a deeper 
understanding of disease progression, diagnostics and is highly beneficial in the area of 
drug development.141  In order to achieve this, a method of detection that is sensitive, 
reproducible and allows for high-throughput analysis is required.  The development of 
enzyme-linked immunosorbent assays (ELISA) combined with Raman spectroscopy has 
allowed for the detection and quantification of disease biomarkers.  Recently, replacing 
the colorimetric detection with resonance Raman scattering (RRS) in a conventional 
ELISA has proved successful for the detection of tumouȽȋ	- ȽȌǡ
inflammatory cytokine related to inflammatory diseases.142  Furthermore, this detection 
method was combined with microarray technology for the detection of prostate specific 
antigen (PSA).143  Since the intensity of the resonance enhanced Raman bands was 
proportional to the protein concentration, protein quantification was possible with low 
limits of detection achieved in both examples: 90 fg/mL and 25 pg/mL for TNF- Ƚ
PSA, respectively.  As well as RRS, SERS has also been used for the analysis of the 
coloured products generated in an ELISA, to improve the sensitivity over the generally 
utilised colorimetric detection.132, 144  
Additionally, SERS-based immunoassays have been developed to combine the 
specificity and convenience of immunoassays with the advantages of SERS in sensitivity 
and the potential for multiplexing.145  The SERS-based immunoassay platform has been 
used to detect protein biomarkers such as immunoglobulin G (IgG) and prostate-specific 
antigen (PSA) to very low limits of detection (approximately 1 pg/mL).146, 147  In 2005, 
Porter et al. developed a SERS-based immunoassay for the detection of feline calicivirus 
(FCV), which causes upper respiratory infections in cats.148  FCV could be compared to 
that of the human calicivirus, associated with gastroenteritis, in that it is highly 
contagious but difficult to study as the virus does not grow in cell culture.  This was the 
first report of low-level detection of an intact viral pathogen in a sandwich 
immunoassay format using SERS as the readout method. 
Following this, they used the SERS-based immunoassay format to detect the pancreatic 
cancer marker MUC4, a mucin protein.149  This proved to be a simple diagnostic test for 
MUC4, providing rapid results from the SERS readout.  This was the first report of 
detecting MUC4 in serum samples from patients.  The results showed that serum from 
patients with pancreatic cancer produced significantly higher SERS response 
corresponding to the presence of MUC4, compared to the SERS results from the analysis 
of serum samples from healthy patients.  This assay was shown to have significant 
advantages compared to the conventional immunoassay detection methods, with 
respect to the limits of detection, analysis time and the amount of sample volume 
required.  Moreover, the assay has the potential to be used for the detection of other 
cancer biomarkers.  More recently, further optimisation was performed on the 
aforementioned SERS-based immunoassay for the detection of MUC4 that involved the 
addition of a smooth mica surface to further increase the reproducibility and sensitivity 
(Figure 10).150  It was reported that the presence of either a polymer or graphene 
monolayer as the thin protective layer further improved the sensitivity and allowed for 
a more stable signal from the Raman reporter (nitrobenzenethiol, NBT) to be obtained.  
The assay was applied for the detection of MUC4 from patient serum samples and, once 
again, the samples from healthy individuals could be clearly distinguished from those of 
patients with pancreatic cancer. 
    
 
Figure 10. Scheme showing the design of the SERS-based nano-immunoassay: (A) a gold capture substrate modified 
with linker molecules and antibodies; (B) gold nanoparticles functionalised with Raman reporter molecules and specific 
antibodies (ERLs); and (C) sandwich immunoassay where antibodies on the capture surface first bind the antigen and 
subsequently bind the ERL.  (D) The sandwich assay produces a SERS readout with several characteristic bands from the 
Raman reporter molecule, NBTǤɋȋ2)Ȅ a symmetric nitro stretch at 1336 cm ?1.150  Reprinted 
from Nanomedicine: Nanotechnology, Biology and Medicine, Vol 11, Alexey V. Krasnoslobodtsev,María P. 
Torres,Sukhwinder Kaur,Ivan V. Vlassiouk,Robert J. Lipert,Maneesh Jain,Surinder K. Batra,Yuri L. Lyubchenko, Nano-
immunoassay with improved performance for detection of cancer biomarkers, Pages 167-173, Copyright © 2015, with 
permission from Elsevier. 
 
Multiplex Detection of Proteins by SERS 
Due to the rapid development of SERS-based immunoassays, they have been shown as 
an extremely desirable method for the simultaneous detection of multiple biomarkers.  
Wu et al. have reported success using the SERS-based immunoassay format by 
designing novel SERS substrates, consisting of Au@Ag core-shell nanorods, that are 
highly SERS-active and chemically stable.151  The simultaneous detection of the tumour 
suppressor p53 and the cyclin-dependent kinase inhibitor p21 was achieved using these 
nanorod substrates that were functionalised with antibodies specific to the two targets 
and two different Raman reporters, 4-mercaptobenzoic acid (4-Ȍ   ?ǡ ?ǯ-
dithiobis(2-nitrobenzoic acid) (DTNB).152  High levels of specificity, reproducibility, and 
sensitivity (LOD 1 pg/mL) were achieved using the SERS-immunoassay format.  These 
outcomes proved to be highly desirable in cancer diagnostics where the combined 
detection and quantification of p53 and p21 would be extremely informative for early 
cancer predictions.  More recently, Wu et al. have developed a multiplex immunoassay 
using SERS and a 3D barcode chip on a microfluidic platform to allow for multiplexed 
high-throughput protein biomarker analysis.153  Multiple proteins present in different 
samples were spatially separated using a microfluidic device that contained specific 
antibody patterns, allowing for the formation of a 2D hybridisation array when the 
target analyte is present.  The novel method was used for the multiplex detection of 
human IgG, mouse IgG and rabbit IgG by using the unique spectral Raman bands of 4-
MBA, DTNB and 2-naphthalenethiol (2-NAT), respectively. 
By exploiting the robust synthesis and functionalisation methods available when 
designing a substrate to be used in SERS analysis, unique designs have been reported 
that allow for the highly sensitive detection and quantification of biomarkers in a SERS-
based immunoassay format.  Fluorescent dyes and Raman active small molecules have 
been combined to create highly sensitive, selective and multifunctional substrates 
known as fluorescent surface enhanced Raman spectroscopic (F-SERS) dots that are 
ideal for multiplexing, as well as tracking and imaging of cellular and molecular 
events.50  F-SERS dots have been used to simultaneously detect three cellular proteins: 
CD34, Sca-1 and SP-C, which are all expressed in bronchioalveolar stem cells (BASCs).  
Antibody-functionalised paramagnetic nanoparticles have also been used in conjunction 
with Raman reporter-functionalised gold nanoparticles for the detection of antigens 
specific to West Nile Virus (WNV) and Rift Valley fever virus (RVFV), with limits of 
detection as low as 5 fg/mL when the assay was performed in salt buffer and 25 pg/mL 
when the biomarkers were present in buffer spiked with fetal bovine serum.154  SERS 
was combined with hollow-core photonic crystal fiber (HCPCF) to enable the 
ultrasensitive detection of hepatocellular carcinoma (HCC) biomarkers: alpha-
fetoprotein (AFP) and alpha-1-antitrypsin (A1AT).155  One of the main advantages 
highlighted when using SERS and HCPCF is the extremely low sample volume required, 
approximately 20 nL, which is highly desirable in clinical diagnostics where samples are 
likely to be small with low amounts of target protein, combined with a lack of 
amplification methods available for proteins.  Guarrotxena et al. designed SERS ǲǳ       ǣ  Ƚ  ȋȌǢ 
myoglobin (MYG) and C-reactive protein (CRP), using three different Raman 
reporters.156   ǲǳ    les functionalised with 
antigen-specific antibodies and are held together by dithiolated Raman reporters.  The 
detection method was in the form of a sandwich immunoassay where protein-specific 
capture antibodies were immobilised onto an epoxy-functionalised glass substrate.  A 
solution that contained a combination of target proteins was exposed to the surface; 
followed by the addition of the ǲǳ   Ǥ     ǲǳ ǡ      ǲǳǤ 
particular assay was tested and limits of detection around 100 pM were obtained.  The 
level of sensitivity of the SERS-based immunoassay platform was recently further tested 
by Xu et al., where the presence of DNA aptamers induced the self-assembly of silver 
pyramids that enabled the multiplexed and ultrasensitive SERS detection of three 
disease biomarkers.157  The three targets were: prostate specific antigen (PSA), 
thrombin and mucin-1, which were detected by monitoring the Raman spectra of 4-
aminothiophenol (4-ATP), 4-nitrothiophenol (4-NTP) and 4-methoxy-Ƚ-toluenethiol 
(MATT), respectively.  The limits of detection for each target were all found to be in the 
attomolar range (Figure 11).  This level of sensitivity is remarkable and extremely 
beneficial in the analysis of clinical samples. 
 
 
Figure 11. A) SERS encoded pyramids for solo biomarker detection.  B) SERS spectra of simultaneous multiplex 
biomarkers detection.  C) Standard curves of SERS encoded pyramidal detection for the SERS signatures intensities 
versus the concentration of PSA (at 1095 cm ?1, left), thrombin (at 1346 cm ?1, middle) and mucin-1 (at 1621 cm ?1, 
right).157 Reprinted by permission of John Wiley and Sons. Copyright © 2015 WILEY-VCH Verlag GmbH & Co. KGaA, 
Weinheim. 
 
Porter et al. had similar success using SERS-based immunoassays for the simultaneous 
detection of multiple biomarkers.  One such approach was based on the self-assembly of 
mixed monolayers.47  A new functionalisation method was developed for the design of 
extrinsic Raman labels (ERLs, Figure 10).  The conventional method involves coating 
gold nanoparticles with both Raman reporter molecules and antigen-specific antibodies 
that each possess thiolates to allow for surface adsorption.  The new method involves 
two thiolates: one thiolate is the bifunctional compound dithiobis(succinimidyl 
propionate) (DSP) that contains both disulphide and succinimidyl functionalities, 
allowing for surface adsorption onto the gold nanoparticle surface and covalent 
coupling of the antibody to the gold nanoparticle; the other thiolate is a molecule that 
has a large Raman cross section to act as a reporter, as DSP is a relatively weak Raman 
active molecule.  By using the newly designed ERLs, a tetraplex was developed for the 
detection of four different targets: mouse IgG, human IgH, rabbit IgG and rat IgG.  The 
limits of detection were all calculated to be in the ng/mL range; however, it was noted 
that the level of sensitivity for each target present in the multiplex decreased compared 
to the targets being detected individually.  This was attributed to the increase in the 
background in the multiplex spectra.47  More recently, Porter et al. have developed a 
SERS-based immunoassay for the detection of two pancreatic cancer biomarkers: serum 
carbohydrate antigen 19-9 (CA 19-9) and matrix metalloproteinase 7 (MMP-7).158  A 
comparison was made between the SERS-based method and the conventional ELISA 
method to demonstrate the increase in sensitivity when the chosen readout method is 
SERS.  The limits of detection of each target when using the SERS-based immunoassay 
were 2.28 pg/mL and 34.5 pg/mL for MMP-7 and CA 19-9, respectively.  Comparing 
these to the values obtained when using the standard ELISA method (MMP-7: 
31.8 pg/mL, CA 19-9: 987 pg/mL), the increase in sensitivity that SERS offers as a 
method of detection was clearly demonstrated. 
 
CONCLUSIONS 
SERS offers many advantages over alternative methods for the detection of biologically 
relevant targets, particularly for multiplex detection.  The technique has been 
successfully applied for the sensitive and specific detection of biomolecules, such as 
DNA and proteins, over a number of years and significant progress has been made on 
improving the sensitivity of detection as well as applying the method for the detection 
of multiple target molecules from one sample.  Recent advancements have seen the 
application of the technique for the detection of multiple targets from real clinical 
samples, which is of paramount importance if the technique is to be applied for 
molecular diagnostics.  The multiplexing capability is due to the specificity of the 
technique which is essential for disease detection and diagnosis.  For example, 
increased levels of CRP alone may be indicative of various conditions involving 
inflammation; however, detection of CRP along with other biomarkers, such as cardiac 
troponin I (cTnI) and/or B-type natriuretic peptide (BNP), could signify the presence of 
a cardiovascular disease.   Therefore, by being able to detect multiple biomarkers 
simultaneously, a more accurate diagnosis can be made.  One of the main advantages of 
SERS is the ability to directly analyse biological samples with minimal sample 
preparation, which is extremely useful for clinicians.  The sensitivity is also of great 
interest to the end user although sometimes the dynamic range may be more important, 
depending on the clinically relevant concentration of the target.  Nonetheless, sensitivity 
and reproducibility allow for quantitative analysis which can be imperative in 
distinguishing between healthy and diseased samples.  Future progress in the field will 
likely expand each of these capabilities and we can expect to see more examples of the 
technique being applied to biological samples for the detection of multiple disease-
related targets.  Furthermore, advances in instrumentation could allow for quick and 
cost-effective analysis which could potentially be carried out at a bedside.  This could 
provide an excellent tool in the field of diagnostics and will open up potential 
opportunities for the use of the technique in clinical applications.  Potential issues such 
as interference, stability of SERS substrates and toxicity of nanoparticles may be of 
concern, although it is expected that these will be overcome with the ongoing 
developments in the field, particularly due to improvement in understanding of 
nanoparticle synthesis, surface chemistry and functionalisation. 
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